Cyclacel Pharmaceuticals Inc (CYCC)
2.122
-0.13
(-5.69%)
USD |
NASDAQ |
May 22, 16:00
2.17
+0.05
(+2.26%)
After-Hours: 20:00
Cyclacel Pharmaceuticals Cash from Financing (Quarterly): -0.079M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.079M |
| December 31, 2023 | 0.999M |
| September 30, 2023 | -0.05M |
| June 30, 2023 | -0.051M |
| March 31, 2023 | -0.05M |
| December 31, 2022 | 0.042M |
| September 30, 2022 | 1.532M |
| June 30, 2022 | 1.474M |
| March 31, 2022 | -0.05M |
| December 31, 2021 | 0.887M |
| September 30, 2021 | 2.904M |
| June 30, 2021 | -0.051M |
| March 31, 2021 | 18.00M |
| December 31, 2020 | 11.35M |
| September 30, 2020 | -0.05M |
| June 30, 2020 | 18.26M |
| March 31, 2020 | -0.05M |
| December 31, 2019 | -0.05M |
| September 30, 2019 | -0.057M |
| June 30, 2019 | -0.101M |
| March 31, 2019 | 4.056M |
| December 31, 2018 | 0.58M |
| September 30, 2018 | -0.05M |
| June 30, 2018 | -0.051M |
| March 31, 2018 | -0.05M |
| Date | Value |
|---|---|
| December 31, 2017 | 0.148M |
| September 30, 2017 | 13.64M |
| June 30, 2017 | 0.926M |
| March 31, 2017 | 0.036M |
| December 31, 2016 | 1.503M |
| September 30, 2016 | 5.037M |
| June 30, 2016 | 0.104M |
| March 31, 2016 | -0.05M |
| December 31, 2015 | 0.434M |
| September 30, 2015 | 0.17M |
| June 30, 2015 | -0.127M |
| March 31, 2015 | 10.38M |
| December 31, 2014 | 1.385M |
| September 30, 2014 | -0.05M |
| June 30, 2014 | 9.239M |
| March 31, 2014 | 1.626M |
| December 31, 2013 | 1.951M |
| September 30, 2013 | 3.078M |
| June 30, 2013 | 19.02M |
| March 31, 2013 | 3.285M |
| December 31, 2012 | 1.041M |
| September 30, 2012 | 0.014M |
| June 30, 2012 | -0.025M |
| March 31, 2012 | 2.945M |
| December 31, 2011 | 0.009M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.101M
Minimum
Jun 2019
18.26M
Maximum
Jun 2020
2.74M
Average
-0.05M
Median
Dec 2019
Cash from Financing (Quarterly) Benchmarks
| Corvus Pharmaceuticals Inc | 0.00 |
| Oragenics Inc | 1.653M |
| Relmada Therapeutics Inc | 0.2217M |
| Alpine Immune Sciences Inc | 19.35M |
| MAIA Biotechnology Inc | 4.717M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.483M |
| Free Cash Flow | -9.734M |
| Free Cash Flow Per Share (Quarterly) | -0.3722 |
| Free Cash Flow to Equity (Quarterly) | -0.483M |
| Free Cash Flow to Firm (Quarterly) | -0.483M |
| Free Cash Flow Yield | -474.7% |